Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ferric carboxymaltose · 1 trial · 1 indication
Measured by Cmax - The maximum plasma concentration of iron
Plasma Pharmacokinetics (PK) of study medication: Area Under the Plasma Concentration-time Curve (AUC)
| Arm | Type | Description |
|---|---|---|
| Ferric carboxymaltose (test) | EXPERIMENTAL | Patients will receive a single dose of Ferric carboxymaltose |
| Ferric carboxymaltose (reference) | ACTIVE_COMPARATOR | Patients will receive a single dose of Ferric carboxymaltose |
| Name | Type | Description |
|---|---|---|
| Ferric carboxymaltose | DRUG | 750 mg/15 mL |
Inclusion Criteria: * Male and female patients at least 18 - 65 years of age; * Patients with a body mass index (BMI) between 18.5 - 35 and with a body weight of ≥50 kg - ≤130 kg; Exclusion Criteria: * Patients with known hypersensitivity to ferric carboxymaltose, excipients, or similar product *...
Ferric carboxymaltose is used for the treatment of Iron Deficiency Anemia. It is an investigational small molecule being developed by Novartis AG. The drug is currently in Phase 1 clinical development, and it has been studied in patients with this condition.
Ferric carboxymaltose is being developed by Novartis AG, which is publicly traded under the ticker symbol NVS. The company is conducting clinical research on this drug for the treatment of Iron Deficiency Anemia.
Ferric carboxymaltose is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The drug is being studied for the treatment of Iron Deficiency Anemia.
Ferric carboxymaltose has been studied in one clinical trial, NCT03399084, which was a Phase 1 study comparing two formulations of the drug in patients with Iron Deficiency Anemia. The trial was completed and enrolled 71 participants in the United States.
Ferric carboxymaltose is also known as iron carboxymaltose. The drug is being developed by Novartis AG for the treatment of Iron Deficiency Anemia and is currently in Phase 1 clinical development.